All data are based on the daily closing price as of October 8, 2025
h
Handa Pharmaceuticals
6620.TWO
4.68 USD
-0.20
-4.10%
Overview
Last close
4.68 usd
Market cap
659.76M usd
52 week high
4.88 usd
52 week low
1.57 usd
Target price
6.54 usd
Valuation
P/E
34.1232
Forward P/E
N/A
Price/Sales
16.9416
Price/Book Value
5.3641
Enterprise Value
649.47M usd
EV/Revenue
14.8485
EV/EBITDA
25.6402
Key financials
Revenue TTM
43.74M usd
Gross Profit TTM
39.65M usd
EBITDA TTM
25.40M usd
Earnings per Share
0.14 usd
Dividend
0.05 usd
Total assets
N/A usd
Net debt
N/A usd
About
Handa Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development of drugs for various diseases in the United States. The company offers ONCORE, a proprietary drug delivery technology that was developed to improve the patient compliance and safety of the tyrosine kinase inhibitor of oncology drugs; Tascenso ODT for the treatment of multiple sclerosis; and HND-033, HND-039, and HND-027 for oncology diseases. It also provides Quetiapine XR to treat Schizophrenia; Dexlansoprazole DR capsules to treat erosive esophagitis and heartburn associated with symptomatic non-erosive gastroesophageal reflux disease; HND-004 for treating diabetes; HND-032 for smoking cessation; and HND-026, a GI drug. Handa Pharmaceuticals, Inc. was founded in 2014 and is headquartered in Tainan City, Taiwan.